3/18
08:00 am
tlsi
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
Medium
Report
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
3/12
04:03 am
tlsi
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating [Yahoo! Finance]
Medium
Report
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating [Yahoo! Finance]
3/7
02:59 am
tlsi
Medium
Report
3/6
03:00 pm
tlsi
TriSalus Life Sciences (TLSI) had its price target lowered by Canaccord Genuity Group Inc. from $12.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
TriSalus Life Sciences (TLSI) had its price target lowered by Canaccord Genuity Group Inc. from $12.00 to $7.00. They now have a "buy" rating on the stock.
3/6
12:34 am
tlsi
TriSalus Life Sciences Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
TriSalus Life Sciences Q4 Earnings Call Highlights [Yahoo! Finance]
3/6
12:23 am
tlsi
TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
3/5
06:29 pm
tlsi
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/5
04:35 pm
tlsi
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]
Medium
Report
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance [Yahoo! Finance]
3/5
04:01 pm
tlsi
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
Medium
Report
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
2/25
04:05 pm
tlsi
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
Low
Report
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
2/20
08:00 am
tlsi
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
High
Report
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
2/19
04:01 pm
tlsi
TriSalus Life Sciences Proposes Public Offering
High
Report
TriSalus Life Sciences Proposes Public Offering
2/9
09:00 am
tlsi
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
Medium
Report
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
2/8
02:04 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall
Medium
Report
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall
1/31
01:33 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at
Wall St
Medium
Report
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at
Wall St
1/17
01:11 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall
Medium
Report
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall
1/12
07:00 am
tlsi
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
Low
Report
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance